Novartis CEO Vas Narasimhan says that Europe needs a “complete rethink” on how it prices its drugs, warning that the entrance of new pharmaceuticals into its markets could be delayed. More: Novartis CEO calls for 'complete rethink' of Europe's drug
read morePfizer now anticipates its Vyndamax sales to remain “relatively stable” from 2028 through mid-2031, it said. More: Pfizer’s victory in delaying Vyndamax generics is mixed bag for BridgeBio: analysts Source: fierce
read moreThe FDA has released briefing documents detailing its concerns for AstraZeneca’s cancer drugs camizestrant and Truqap ahead of an upcoming advisory committee meeting, the first such gathering in about nine months. More: FDA flags concerns for AstraZeneca's camizestrant, Truqap ahead
read moreThe FDA has told Amgen that it is proposing to withdraw the approval of the rare disease drug Tavneos. The FDA cited new information that indicates that data was “manipulated” to facilitate the approval of Tavneos. In addition, the FDA is
read moreRocket Pharmaceuticals has offloaded its lucrative FDA rare pediatric disease priority review voucher, striking a $180 million sale that reflects the high market demand for a speedy FDA review. More: Rocket sells priority review voucher for 0M after Kresladi gene
read more
Lead asset shows systemic, dose‑dependent anti‑tumour activity More: Asgard Therapeutics to present new preclinical data on AT‑108 at ASGCT 2026 Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals